Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines
Abstract Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.
Isolation of Pseudomonas aeruginosa after nontuberculous mycobacteria
The International Journal of Tuberculosis and Lung Disease | May 4, 2022 | Volume: 26 | Issue: 5 | Pages: 460-462
Pulmonary Nontuberculous Mycobacterial Infection in Patients in the U.S. Bronchiectasis Research Registry: Use of Antibiotic Therapy and Adverse Events
B106. BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A4358-A4358
The Validity of Claims-Based Codes to Identify Pseudomonas Infection in Patients with Bronchiectasis in Medicare Data
C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5697-A5697
Abstract Nontuberculous mycobacteria (NTM) cause an increasingly important chronic and debilitating lung disease in older adults. Diagnosis is often delayed, although awareness among clinicians and patients is increasing. When necessary, treatment often lasts 18–24 months and consists of three or four antibiotics that can have serious side effects. Relapses are common and commonly require resumption of prolonged therapy. Given the need for improved diagnostic techniques and clinical trials to identify new therapies or to improve existing therapies, a group of North American clinicians and researchers formed the NTM Research Consortium (NTMRC) in 2014. The NTMRC recognized the importance of including the patient voice in determining research priorities for NTM. In November 2015, patients, caregivers, patient advocates, clinical experts, and researchers gathered for a 1-day meeting in Portland, Oregon funded by the Patient-Centered Outcomes Research Institute. The meeting goal was to define patient-centered research priorities for NTM lung infections. Patients expressed frustration with the number of people who have endured years of missed diagnoses or inadequate treatment of NTM. Participants identified as top research priorities the prevention of NTM infection; approval of more effective treatments with fewer side effects and easier administration; understanding the best chest physiotherapy methods; validating and using tools to measure quality of life; and developing a disease-specific activity and severity assessment tool. Workshop participants agreed that two complementary objectives are critical to ensure the best achievable outcomes for patients: (1) additional clinician education to improve screening and diagnosis of NTM infections; and (2) development of a geographically distributed network of experts in NTM disease to offer consultation or direct therapy after a diagnosis is made.